These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 10388176)

  • 41. Cost-effectiveness of breast cancer screening in women on dialysis.
    Wong G; Howard K; Chapman JR; Craig JC
    Am J Kidney Dis; 2008 Nov; 52(5):916-29. PubMed ID: 18789566
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mammography screening: are women really giving informed consent? (Counterpoint).
    Berg AO
    J Natl Cancer Inst; 2003 Oct; 95(20):1511-2; discussion 1512-3. PubMed ID: 14559871
    [No Abstract]   [Full Text] [Related]  

  • 43. Informed consent for mammography screening: modelling the risks and benefits for American women.
    Marshall T
    Health Expect; 2005 Dec; 8(4):295-305. PubMed ID: 16266417
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mammography screening: are women really giving informed consent?
    Baines CJ
    J Natl Cancer Inst; 2003 Oct; 95(20):1508-11. PubMed ID: 14559870
    [No Abstract]   [Full Text] [Related]  

  • 45. Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality.
    Tabár L; Vitak B; Chen HH; Yen MF; Duffy SW; Smith RA
    Cancer; 2001 May; 91(9):1724-31. PubMed ID: 11335897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mammographic screening after the age of 65 years: evidence for a reduction in breast cancer mortality.
    Van Dijck JA; Verbeek AL; Beex LV; Hendriks JH; Holland R; Mravunac M; Straatman H; Werre JM
    Int J Cancer; 1996 Jun; 66(6):727-31. PubMed ID: 8647640
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discussing the benefits and harms of screening mammography.
    Brennan M; Houssami N
    Maturitas; 2016 Oct; 92():150-153. PubMed ID: 27621253
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Body mass index and breast cancer survival in relation to the introduction of mammographic screening.
    Olsson A; Garne JP; Tengrup I; Zackrisson S; Manjer J
    Eur J Surg Oncol; 2009 Dec; 35(12):1261-7. PubMed ID: 19481409
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mammographic screening for breast cancer. Overdiagnosis: an insidious adverse effect of screening.
    Prescrire Int; 2015 Jul; 24(162):186-9, 191. PubMed ID: 26240891
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Benefits and Harms of Breast Cancer Screening: A Systematic Review.
    Myers ER; Moorman P; Gierisch JM; Havrilesky LJ; Grimm LJ; Ghate S; Davidson B; Mongtomery RC; Crowley MJ; McCrory DC; Kendrick A; Sanders GD
    JAMA; 2015 Oct; 314(15):1615-34. PubMed ID: 26501537
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Informed decision making: age of 50 is arbitrary and has no demonstrated influence on breast cancer screening in women.
    Kopans DB
    AJR Am J Roentgenol; 2005 Jul; 185(1):177-82. PubMed ID: 16060005
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Organized breast cancer screening].
    Rouëssé J; Sancho-Garnier H;
    Bull Acad Natl Med; 2014 Feb; 198(2):369-86. PubMed ID: 26263710
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mammography screening: are women really giving informed consent? (Countering the counterpoint).
    Baines CJ
    J Natl Cancer Inst; 2003 Oct; 95(20):1512-3. PubMed ID: 14559872
    [No Abstract]   [Full Text] [Related]  

  • 54. Screening younger women at risk for breast cancer.
    Vogel VG
    J Natl Cancer Inst Monogr; 1994; (16):55-60. PubMed ID: 7999470
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Organised mammographic screening--more benefits than harms.
    Hofvind S
    Tidsskr Nor Laegeforen; 2013 Mar; 133(6):619-20. PubMed ID: 23552154
    [No Abstract]   [Full Text] [Related]  

  • 56. The Swedish Two-County Trial of mammographic screening: cluster randomisation and end point evaluation.
    Duffy SW; Tabar L; Vitak B; Yen MF; Warwick J; Smith RA; Chen HH
    Ann Oncol; 2003 Aug; 14(8):1196-8. PubMed ID: 12881376
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Balancing the benefits and detriments among women targeted by the Norwegian Breast Cancer Screening Program.
    Hofvind S; Román M; Sebuødegård S; Falk RS
    J Med Screen; 2016 Dec; 23(4):203-209. PubMed ID: 26940960
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mammographic screening: patterns of use and estimated impact on breast carcinoma survival.
    Blanchard K; Colbert JA; Puri D; Weissman J; Moy B; Kopans DB; Kaine EM; Moore RH; Halpern EF; Hughes KS; Tanabe KK; Smith BL; Michaelson JS
    Cancer; 2004 Aug; 101(3):495-507. PubMed ID: 15274062
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials.
    de Koning HJ; Boer R; Warmerdam PG; Beemsterboer PM; van der Maas PJ
    J Natl Cancer Inst; 1995 Aug; 87(16):1217-23. PubMed ID: 7563167
    [TBL] [Abstract][Full Text] [Related]  

  • 60. How information about overdetection changes breast cancer screening decisions: a mediation analysis within a randomised controlled trial.
    Hersch J; McGeechan K; Barratt A; Jansen J; Irwig L; Jacklyn G; Houssami N; Dhillon H; McCaffery K
    BMJ Open; 2017 Oct; 7(10):e016246. PubMed ID: 28988168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.